Delivery Order SPE2DB24D9212-SPE2DB25FBUCV

Award Date 2/7/25
Potential Completion Date 3/3/25
Potential Value $4.2K
Ultimate Awardee
Not listed
Federal Contract Vehicle
Set-Aside Type
No Set-Aside Used
Extent Competed
Full and Open Competition
Major Defense Program
Not listed
Pricing Type
Firm Fixed Price
Place of Performance
Park Ridge, IL 60068, USA
Solicitation Procedures
Negotiated Proposal / Quote
Number Of Offers Received
Not listed
Legislative Mandate
Not listed
National Interest Action
Not listed
Research Type
Not listed
Primary Consortia Member
Not listed
Similar Awards
This is a firm fixed-price delivery order awarded by the Defense Logistics Agency (DLA) to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois. The $4,165.86 contract is for the delivery of NEXPLANON 68 MG IMPLANTS, a contraceptive product, with a performance period ending on January 29, 2025. DMS Pharmaceutical Group Inc. holds a larger $499,999,999 Indefinite Delivery Contract (IDC) with the DLA under the SPE2DB program, which...
This is a firm fixed-price delivery order awarded by the Defense Logistics Agency (DLA) to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois. The contract, valued at $2,144.07, is for the delivery of NEXPLANON 68 MG IMPLANTS, a prescription contraceptive device, with a completion date of January 2, 2025. DMS Pharmaceutical Group Inc. holds a $499,999,999 Indefinite Delivery Contract (IDC) with the DLA under the SPE2DB program,...
This is a firm fixed-price delivery order awarded by the Defense Logistics Agency (DLA) to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois. The order is for the supply of 4,566,524,761 units of the NEXPLANON 68 MG IMPLANTS contraceptive device, with a ceiling value of $1,429.38 and a period of performance through December 11, 2024. DMS Pharmaceutical Group Inc. holds a larger Indefinite Delivery Contract (IDC) with the DLA under...
This is a firm fixed-price delivery order awarded by the Defense Logistics Agency (DLA) to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois. The $8,576.28 contract is for the supply of 4,565,546,802 Nexplanon 68 mg implants, a contraceptive device, with a period of performance through August 23, 2024. DMS Pharmaceutical Group holds a larger indefinite delivery contract (IDC) with the DLA under the SPE2DB program, valued at up...
This is a firm fixed-price delivery order awarded by the Defense Logistics Agency (DLA) to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois. The $6,837.40 contract is for the delivery of NEXPLANON 68 MG IMPLANTS, a type of contraceptive implant, with a completion date of October 18, 2023. DMS Pharmaceutical Group holds a larger $499,999,999 Indefinite Delivery Contract (IDC) with the DLA under the SPE2DB program, which enables...
This is a firm fixed-price delivery order awarded to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler, by the Defense Logistics Agency (DLA). The $4,786.18 contract is for the supply of NEXPLANON 68 MG IMPLANTS, a contraceptive product, with an ultimate completion date of October 5, 2023. DMS Pharmaceutical Group holds a significant $499,999,999 indefinite delivery contract (IDC) with the DLA under the SPE2DB program, which allows the agency to issue delivery...
This is a contract award by the Defense Logistics Agency (DLA) to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler. The $1,429.38 firm fixed-price delivery order is for 4,565,089,397 units of the Nexplanon 68 MG contraceptive implant, with a period of performance through July 24, 2024. This award is under a single-award indefinite delivery contract (IDC) valued at up to $499,999,999 held by DMS Pharmaceutical Group with the DLA, which allows the agency to...
This is a firm fixed-price delivery order awarded to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois. The $7,984.32 contract was awarded by the Defense Logistics Agency (DLA) to provide 4,566,445,964 units of the contraceptive implant NEXPLANON 68 MG for a period ending on December 4, 2024. DMS Pharmaceutical Group holds a significant $499,999,999 Indefinite Delivery Contract (IDC) with the DLA under the SPE2DB program, which...
This is a firm fixed-price delivery order contract awarded by the Defense Logistics Agency (DLA) to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois. The contract is for the delivery of NEXPLANON 68 MG IMPLANTS, a contraceptive implant, with a ceiling value of $7,550.16 and a period of performance through March 28, 2022. DMS Pharmaceutical Group Inc. holds a larger $499,999,999 Indefinite Delivery Contract (IDC) with the DLA...
This is a $12,307.32 firm fixed-price delivery order contract awarded by the Defense Logistics Agency (DLA) to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois. The contract is for the delivery of 4,560 units of the NEXPLANON 68 MG IMPLANTS contraceptive device, with a period of performance through March 15, 2023. This delivery order is issued under DMS Pharmaceutical Group's $499,999,999 Indefinite Delivery Contract (IDC) with...
  • SPE2DB24D9212
    Indefinite Delivery Contract
  • SPE2DB24D9212-SPE2DB25FBUCV
    Delivery Order

This is a firm fixed-price delivery order awarded by the Defense Logistics Agency (DLA) to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler. The $4,165.86 contract is for the delivery of 4,567,229,402 units of NEXPLANON 68 MG IMPLANTS, a contraceptive device, with a period of performance through March 3, 2025.

DMS Pharmaceutical Group Inc. holds a larger $499,999,999 Indefinite Delivery Contract (IDC) with the DLA under the SPE2DB program, which allows the agency to issue firm fixed-price delivery orders for a comprehensive range of pharmaceutical products, including branded and generic prescription drugs, over-the-counter medications, biologics, and medical consumables. This specific award is not associated with any set-aside designation, allowing DMS Pharmaceutical Group to leverage its woman-owned small business status to secure direct federal contracts across various medical product categories.

Generated 5/9/25, 10:11 AM